To appraise the clinical and cost effectiveness of alectinib within its marketing authorisation for untreated, anaplastic lymphoma kinase-positive (ALK positive) advanced non-small-cell lung cancer.
Status In progress
Process STA pre-2018
ID number 925

Provisional Schedule

Expected publication 08 August 2018

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Roche Products (alectinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies Pfizer (crizotinib)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
28 June 2018 - 12 July 2018 Final appraisal determination
06 April 2018 - 26 April 2018 Appraisal consultation: 1
08 March 2018 Committee meeting
18 December 2017 The company, Roche, has identified a modelling error in its submission and require more time to correct this. As a consequence, the evidence review group (ERG) will require more time to prepare their ERG report. Therefore, we have rescheduled the first appraisal committee meeting discussion for this topic to 8 March 2018.
26 September 2017 Invitation to participate
20 September 2017 In progress, In Progress
31 July 2017 - 29 August 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 July 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance